Peripheral artery disease, often abbreviated as PAD, is a condition in which atherosclerosis, the buildup of fatty plaques inside artery walls, reduces blood flow to the limbs. A review published in the European Heart Journal describes it as a prevalent but chronically undertreated manifestation of systemic atherosclerosis that carries elevated risks of both major cardiovascular events and serious limb complications, including amputation.
The review surveys the full landscape of medical approaches researchers are studying to address PAD, from established cholesterol-lowering strategies to anticoagulants to newer classes of metabolic drugs. Among those newer classes, glucagon-like peptide-1 receptor agonists, commonly called GLP-1 RAs, receive notable attention. Early data suggests they may do more than lower blood sugar or reduce body weight. Researchers are now asking whether they can directly lower the rate of limb-threatening events in people with PAD.
This article summarizes the key findings of that review for readers who are curious about the science without a clinical background, with a particular focus on what the literature says about GLP-1 peptides and their potential role in vascular disease research.
What peripheral artery disease involves
PAD develops when the same process that causes heart attacks and strokes, the gradual narrowing of arteries by plaque, affects the vessels supplying the legs, arms, and other peripheral tissues. The review describes it as a manifestation of systemic atherosclerosis, meaning the underlying biology is body-wide, not confined to one location.
Patients with PAD face two overlapping categories of risk. The first is major adverse cardiovascular events, which include heart attacks and strokes. The second is major adverse limb events, which range from severe pain during walking to tissue death and amputation. The review emphasizes that despite both risks being well-documented, PAD remains widely underdiagnosed and undertreated in clinical practice.
The authors argue that effective management requires attacking several biological drivers at once, including metabolic dysfunction, elevated lipids, chronic low-grade inflammation, and the tendency of blood to clot too readily. No single drug addresses all of these pathways, which is why the review advocates for multifaceted, individualized strategies.
GLP-1 receptor agonists and vascular biology
GLP-1 is a peptide hormone produced naturally in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and acts on appetite-regulating centers in the brain. Researchers synthesized longer-acting analogs of this peptide to exploit those properties in a drug format. Those analogs are the GLP-1 receptor agonists now being studied across a wide range of metabolic and cardiovascular conditions.
The European Heart Journal review notes that GLP-1 receptor agonists confer cardiovascular and renal benefits that appear to be at least partly independent of how well they control blood glucose. In other words, researchers observed reductions in cardiovascular events in trial populations even after accounting for changes in blood sugar levels. This observation shifted scientific thinking about these peptides from purely metabolic agents to compounds with potential direct effects on vascular biology.
The mechanisms under investigation include reduced inflammation in artery walls, favorable changes in blood pressure, improvements in endothelial function, and effects on clotting tendency. The review describes the evidence base as emerging rather than definitive, but notes it is substantial enough to prompt continued large-scale research.
Limb event data and what it means
Perhaps the most notable element of the review for PAD specifically is its observation that emerging data suggests GLP-1 receptor agonists may reduce limb events, not just cardiovascular events. Major adverse limb events are harder to study than heart attacks because they are less common as a primary trial endpoint, but the signals appearing in existing data have encouraged researchers to look more carefully.
The review singles out semaglutide, the active peptide in several formulations studied in large cardiovascular outcomes trials, as the only anti-obesity pharmacotherapy demonstrated to reduce cardiovascular events in high-risk patients with overweight or obesity who do not have diabetes. That finding comes from a dedicated trial and represents a meaningful expansion of the research question from glycemic control to broader vascular protection.
For PAD specifically, the limb event data remains early-stage. The review frames it as an area of active investigation rather than established guidance. Still, the biological plausibility is considered strong enough that researchers are designing prospective studies to test the hypothesis more directly.
Where GLP-1 peptides sit alongside other approaches
The review does not position GLP-1 receptor agonists as a standalone solution. Instead, it describes them as one component of a layered strategy. Statins remain the first-line cholesterol-lowering therapy for all PAD patients. When LDL cholesterol targets are not met with statins alone, the review recommends adding agents such as ezetimibe, bempedoic acid, or PCSK9 inhibitors, a class of drugs that block a protein involved in cholesterol regulation.
On the antithrombotic side, the review highlights dual pathway therapy combining low-dose rivaroxaban, an anticoagulant, with aspirin as a strategy shown in trials to reduce both cardiovascular and limb events in patients with high ischemic risk who are not at elevated bleeding risk. This addresses the clotting drivers of PAD separately from the metabolic and lipid drivers.
SGLT2 inhibitors, another class of antidiabetic drugs, are also mentioned for their cardiovascular and renal benefits. The review describes both GLP-1 receptor agonists and SGLT2 inhibitors as providing benefits independent of glycemic control, which makes them relevant to PAD patients whether or not they have diabetes.
A phenotype-driven approach to research design
One of the more conceptually interesting proposals in the review is what the authors call a phenotype-driven approach to PAD management. Rather than treating all PAD patients identically, the review argues that researchers and clinicians should stratify patients by their individual risk profile, including which biological drivers are most prominent, and then match interventions accordingly.
For a patient whose dominant risk factor is metabolic dysfunction and who carries excess body weight, the literature increasingly supports GLP-1 receptor agonists as a well-studied option for addressing multiple risk drivers simultaneously. For a patient whose primary concern is lipid burden, intensified lipid-lowering therapy takes priority. The point is that PAD is not one uniform condition, and the research agenda should reflect that complexity.
This framing also opens the door for combination research strategies that pair different mechanistic approaches. Early data suggests that the anti-inflammatory and vascular effects of GLP-1 peptides could complement the lipid effects of statins and PCSK9 inhibitors in ways that are additive rather than redundant.
What the review does not resolve
The review is candid about the limits of current evidence. While cardiovascular outcome data for GLP-1 receptor agonists is robust across multiple large trials, limb-specific outcome data in PAD populations is still emerging. Researchers have not yet conducted dedicated PAD-focused trials large enough to draw firm conclusions about whether GLP-1 peptides reduce amputation rates or improve walking distance as primary endpoints.
The review also acknowledges that implementation gaps remain a serious problem. PAD is underdiagnosed, which means many people who might benefit from any of these approaches never receive a diagnosis in the first place. Even among diagnosed patients, guideline-recommended therapies are frequently not prescribed at optimal doses or combinations.
For readers interested in the science, the key takeaway from the European Heart Journal review is that GLP-1 receptor agonists represent one of the more active and biologically compelling research frontiers in vascular disease today. The literature suggests they act through mechanisms that go well beyond blood sugar control, and early data pointing toward reduced limb events in PAD populations has given researchers a meaningful hypothesis to pursue in future trials.
